Generating MHC class I ligands from viral gene products

Immunological Reviews

Volumn 172, Issue , 1999, Pages 97-108

  Yewdell, Jonathan ^a   Antón, Luis C ^a   Bacik, Igor ^a   Schubert, Ulrich ^a   Snyder, Heidi Link ^a   Bennink, Jack R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GENE PRODUCT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; PROTEINASE; UBIQUITIN;

ANTIGEN PRESENTATION; ARTICLE; ENDOPLASMIC RETICULUM; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS GENE;

EID: 0033456192     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01359.x     Document Type: Article

References (76)

1. 1. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974;248:701-702.
2. 2. Bennink JR, Yewdell JW, Gerhard W. A viral polymerase involved in recognition of influenza virus-infected cells by a cytotoxic T-cell clone. Nature 1982;296:75-76.
3. 3. Yewdell JW, Bennink JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985;82:1785-1789.
4. 4. Bennink JR, Yewdell JW, Smith GL, Moss B. Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled. J Virol 1987;61:1098-1102.
5. 5. Bennink JR, Yewdell JW, Smith GL, Moss B. Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J Virol 1986;57:786-791.
6. 6. Bennink JR, et al. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 1984;311:578-579.
7. 7. Bennink JR, Yewdell JW. Murine cytotoxic T lymphocyte recognition of individual influenza virus proteins. High frequency of non-responder MHC class I alleles. J Exp Med 1988;168:1935-1939.
8. 8. Yewdell JW, et al. Recognition of cloned vesicular stomatitis virus internal and external gene products by cytotoxic T lymphocytes. J Exp Med 1986;163:1529-1538.
9. 9. Townsend ARM, et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986;44:959-968.
10. 10. Falk K, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-296.
11. 11. Garcia KC, et al. An αβ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 1996;274:209-219.
12. 12. Garboczi DN, et al. Structure of the complex between human T cell receptor, viral peptide, and HLA-A2. Nature 1996;384:134-141.
13. 13. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998;16:323-358.
14. 14. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999;17:739-779.
15. 15. Momburg F, Hammerling GJ. Generation and TAP-mediated transport of peptides for major histocompatibility complex class I molecules. Adv Immunol 1998;68:191-256.
16. 16. Tanaka K, et al. Proteosomes and antigen processing. Adv Immunol 1997;64:1-38.
17. 17. Bogyo M, Gaczynska M, Ploegh HL. Proteasome inhibitors and antigen presentation. Biopolymers 1997;43:269-280.
18. 18. Rammensee H-G, Bachmann J, Stevanovic S. MHC ligands and peptide motifs. Austin (TX): Landes Bioscience; 1997.
19. 19. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998;17:7151-7160.
20. 20. Bonifacino JS, Weissman AM. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu Rev Cell Dev Biol 1998;14:19-57.
21. 21. Fink AL. Chaperone-mediated protein folding. Physiol Rev 1999;79:425-449.
22. 22. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996;381:571-580.
23. 23. Esquivel F, Yewdell JW, Bennink JR. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J Exp Med 1992;175:163-168.
24. 24. Yewdell JW, Bennink JR. Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. Science 1989;244:1072-1075.
25. 25. Antón LC, et al. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J Immunol 1998;160:4859-4868.
26. 26. Yewdell JW, Antón LC, Bennink JR. Defective ribosomal products (DRiPs). A major source of antigenic peptides for MHC class I molecules? J Immunol 1996;157:1823-1826.
27. 27. Mimnaugh EG, et al. Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response. Biochemistry 1997;36:14418-14429.
28. 28. Antón LC, Yewdell JW, Bennink JR. MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. J Immunol 1997;158:2535-2542.
29. 29. Yewdell JW, Bennink JR, Hosaka Y. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 1988;239:637-640.
30. 30. Villanueva MS, Fischer P, Feen K, Pamer EG. Efficiency of MHC class I antigen processing: a quantitative analysis. Immunity 1994;1:479-489.
31. 31. Finley D, Ciechanover A, Varshavsky A. Thermolability of ubiquitin-activating enzyme from the mammalian cell cycle mutant ts85. Cell 1984;37:43-55.
32. 1 ubiquitin-activating enzyme in temperature-sensitive cell lines. J Immunol 1995;154:511-519.
33. 33. Deveraux Q, Wells R, Rechsteiner M. Ubiquitin metabolism in ts85 cells, a mouse carcinoma line that contains a thermolabile ubiquitin activating enzyme. J Biol Chem 1990;265:6323-6329.
34. 34. Realini C, Rogers SW, Rechsteiner M. Proposed roles in protein-protein association and presentation of peptides by MHC class I receptors. FEBS Lett 1994;348:109-113.
35. 35. Day PM, Yewdell JW, Porgador A, Germain RN, Bennink JR. Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells. Proc Natl Acad Sci USA 1997;94:8064-8069.
36. 36. Porgador A, et al. Localization, quantitation, and in situ detection of specfic peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997;6:715-726.
37. 37. Antón LC, et al. Intracellular localization of proteasomal degradation of a viral antigen. J Cell Biol 1999;146:113-124.
38. 38. Yewdell JW, Frank E, Gerhard W. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol 1981;126:1814-1819.
39. 39. Sternsdorf T, Grotzinger T, Jensen K, Will H. Nuclear dots: actors on many stages. Immunobiology 1997;198:307-331.
40. 40. Zheng P, et al. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 1998;396:373-376.
41. 41. Wojcik C, et al. Ubiquitin-mediated proteolysis centers in HeLa cells: indication from studies of an inhibitor of the chymotrypsin-like activity of the proteasome. Eur J Cell Biol 1996;71:311-318.
42. 42. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883-1898.
43. 43. Russ G, et al. Assembly, intracellular localization, and nucleotide binding properties of the human peptide transporters Tap1 and Tap2 expressed by recombinant vaccinia viruses. J Biol Chem 1995;270:21312-21318.
44. 44. Monaco JJ, Nandi D. The genetics of proteasomes and antigen processing. Annu Rev Genet 1995;29:729-754.
45. 45. Yewdell JW, et al. MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient MHC class I restricted-presentation of viral antigens. J Immunol 1994;152:1163-1170.
46. 46. Vinitsky A, et al. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: involvement of nonproteasomal cyosolic proteases in antigen processing? J Immunol 1997;159:554-564.
47. 47. Varshavsky A. The N-end rule: functions, mysteries, uses. Proc Natl Acad Sci USA 1996;96:12142-12159.
48. 48. Townsend A, et al. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med 1988;168:1211-1224.
49. 49. Bush KT, Goldberg AL, Nigam SK. Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J Biol Chem 1997;272:9086-9092.
50. 50. Fu TM, et al. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol 1998;72:1469-1481.
51. 51. Restifo NP, et al. Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol 1995;154:4414-4422.
52. 52. Luckey CJ, et al. Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol. J Immunol 1998;161:112-121.
53. 53. Glas R, et al. A proteolytic system that compensates for loss of proteasome function. Nature 1998;392:618-622.
54. 54. Lopez D, Del Val M. Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation. J Immunol 1997;159:5769-5772.
55. 55. Snyder HL, et al. Two novel routes of TAP-independent-MHC class I antigen processing. J Exp Med 1997;186:1087-1098.
56. 56. Bodmer HC, Pemberton RM, Rothbard JB, Askonas BA. Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein. Cell 1988;52:253-258.
57. 57. Eisenlohr LC, Yewdell JW, Bennink JR. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J Exp Med 1992;175:481-487.
58. 58. Falk K, et al. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J Exp Med 1991;174:425-434.
59. 59. Del Val M, et al. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 1991;66:1145-1153.
60. 60. Sherman LA, Burke TA, Biggs JA. Extracellular processing of antigens that bind class I major histocompatibility molecules. J Exp Med 1992;175:1221-1226.
61. 61. Eisenlohr LC, et al. Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes. Cell 1992;71:963-972.
62. 62. Anderson K, et al. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med 1991;174:489-492.
63. 63. Bacik I, et al. TAP-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino but not carboxy terminus of the peptide. J Immunol 1994;152:381-387.
64. 64. Snyder HL, Yewdell JW, Bennink JR. Trimming of antigenic peptides in an early secretory compartment. J Exp Med 1994;180:2389-2394.
65. 65. Deng Y, et al. Assembly of MHC class I molecules with biosynthesized endoplasmic reticulum-targeted peptides is inefficient in insect cells and can be enhanced by protease inhibitors. J Immunol 1998;161:1677-1685.
66. 66. Guertin DP, Fan DP. Stimulation of cytolytic T cell by isolated viral peptides and HN protein coupled to agarose beads. Nature 1980;283:308-313.
67. 67. Siliciano RF, Soloski MJ. MHC class I-restricted processing of transmembrane proteins. Mechanism and biological significance. J Immunol 1995;155:1-5.
68. 68. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 1992;356:443-446.
69. 69. Henderson RA, et al. HLA-A2.1-associated peptides from a mutant line: a second pathway of antigen presentation. Science 1992;255:1264-1266.
70. 70. Snyder HL, et al. Promiscuous liberation of MHC-class 1-binding peptides from the C termini of membrane and soluble proteins in the secretory pathway. Eur J Immunol 1998;28:1339-1346.
71. 71. Yewdell JW, Bennink JR. Cell biology of antigen processing and presentation to MHC class I molecule-restricted T lymphocytes. Adv Immunol 1992;52:1-123.
72. 72. Bacik I, et al. Introduction of a glycosylation site into a secreted protein provides evidence for a novel antigen processing pathway: transport of precursors of MHC class I restricted-peptides from the endoplasmic reticulum to the cytosol. J Exp Med 1997;186,479-487.
73. 73. McCracken AA, Brodsky JF. Assembly of ER-associated protein degradation in vitro: dependence on cytosol, calnexin, and ATP. J Cell Biol 1996;132:291-298.
74. 74. Wiertz EJHJ, et al. The human cytomegalovirus US1 1 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996;84:769-779.
75. 75. Mosse CA, et al. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol. J Exp Med 1998;187:37-48.
76. CD8 response to infectious agents, tumors, transplants, and vaccines. Adv Immunol 1999;73:1-77.